Availability and coverage of new drugs in 6 high-income countries with health technology assessment bodies
Wouters, O. J.
, Naci, H. & Papanicolas, I.
(2024).
Availability and coverage of new drugs in 6 high-income countries with health technology assessment bodies.
Journal of American Medical Association: Internal Medicine,
184(3), 328 - 330.
https://doi.org/10.1001/jamainternmed.2023.7726
, Naci, H. & Papanicolas, I.
(2024).
Availability and coverage of new drugs in 6 high-income countries with health technology assessment bodies.
Journal of American Medical Association: Internal Medicine,
184(3), 328 - 330.
https://doi.org/10.1001/jamainternmed.2023.7726
Most high-income countries except the US rely on health technology assessment (HTA) to ensure that prices paid for new medicines reflect the value they provide.1,2 Health technology assessment bodies assess the relative clinical or economic impact of new drugs to guide pricing and coverage decisions. These assessments usually occur after marketing authorization by a medicines regulatory body (eg, European Medicines Agency), and patients may have little or no access to therapies not assessed favorably by HTA bodies.